NCT04549363 - Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.

Trial Locations (6)

10065

GSK Investigational Site, New York

21201

GSK Investigational Site, Baltimore

27517

GSK Investigational Site, Chapel Hill

30322

GSK Investigational Site, Atlanta

66205

GSK Investigational Site, Westwood

94143

GSK Investigational Site, San Francisco